Suppr超能文献

载脂蛋白E莱顿与人类血浆极低密度脂蛋白的优先结合。

Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.

作者信息

Fazio S, Horie Y, Weisgraber K H, Havekes L M, Rall S C

机构信息

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

出版信息

J Lipid Res. 1993 Mar;34(3):447-53.

PMID:8468528
Abstract

Apolipoprotein (apo) E Leiden is a rare variant of human apoE characterized by defective receptor binding and associated with dominant transmission of type III hyperlipoproteinemia. In heterozygotes, apoE Leiden is present in higher concentrations in both total plasma and very low density lipoproteins (VLDL) than the other apoE allele product. In the present study we analyzed cell expression and plasma lipoprotein association of apoE Leiden to determine whether the unequal concentration of the two apoE allele products could be explained by differences in secretion rate from the hepatocyte or by preferential association with VLDL. We transfected the rat hepatoma cell line McA-RH7777 with apoE Leiden or normal human apoE3, and studied their secretion and media distribution. In pulse-chase experiments, the secretion of apoE Leiden was comparable to that of both human apoE3 and rat endogenous apoE, approaching 100% in 90 min. In similar transfection experiments, secreted apoE Leiden was significantly less glycosylated than normal apoE3 (21.7% vs. 36.6%, P < 0.005, n = 4), a finding also noted for apoE Leiden in human plasma. In in vitro incubation experiments, apoE Leiden showed a markedly higher preference for VLDL of normolipidemic human plasma when compared to both apoE3 (2.6-fold, P < 0.001) and apoE4 (1.6-fold, P < 0.001). These results suggest that the accumulation of apoE Leiden in VLDL derives from a high affinity of the mutant protein for the VLDL. This enrichment in defective apoE probably exacerbates impairment of VLDL removal from the circulation, thus contributing to the dominant transmission of type III hyperlipoproteinemia.

摘要

载脂蛋白(apo)E莱顿是人类载脂蛋白E的一种罕见变体,其特征是受体结合缺陷,并与III型高脂蛋白血症的显性遗传相关。在杂合子中,与其他载脂蛋白E等位基因产物相比,apoE莱顿在总血浆和极低密度脂蛋白(VLDL)中的浓度更高。在本研究中,我们分析了apoE莱顿的细胞表达和血浆脂蛋白结合情况,以确定两种载脂蛋白E等位基因产物浓度不均是否可以通过肝细胞分泌率的差异或与VLDL的优先结合来解释。我们用apoE莱顿或正常人apoE3转染大鼠肝癌细胞系McA-RH7777,并研究它们的分泌和培养基分布。在脉冲追踪实验中,apoE莱顿的分泌与人apoE3和大鼠内源性apoE的分泌相当,90分钟内接近100%。在类似的转染实验中,分泌的apoE莱顿的糖基化程度明显低于正常apoE3(21.7%对36.6%,P<0.005,n = 4),这一发现也适用于人血浆中的apoE莱顿。在体外孵育实验中,与apoE3(2.6倍,P<0.001)和apoE4(1.6倍,P<0.001)相比,apoE莱顿对正常血脂人血浆的VLDL表现出明显更高的偏好。这些结果表明,apoE莱顿在VLDL中的积累源于突变蛋白对VLDL的高亲和力。这种缺陷性载脂蛋白E的富集可能会加剧VLDL从循环中清除的受损,从而导致III型高脂蛋白血症的显性遗传。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验